A5007668416- Hepatitis B Virus Studies
- Hepatitis C virus research
- Liver Disease Diagnosis and Treatment
- Hepatitis Viruses Studies and Epidemiology
- Liver Disease and Transplantation
- Hepatocellular Carcinoma Treatment and Prognosis
- HIV/AIDS drug development and treatment
- Liver Diseases and Immunity
- Viral gastroenteritis research and epidemiology
- Glutathione Transferases and Polymorphisms
- Animal Virus Infections Studies
- Monoclonal and Polyclonal Antibodies Research
- Immunotherapy and Immune Responses
- Gallbladder and Bile Duct Disorders
- Pancreatic and Hepatic Oncology Research
- Diabetes and associated disorders
- Pancreatitis Pathology and Treatment
- Gastrointestinal disorders and treatments
- Genomics, phytochemicals, and oxidative stress
- SARS-CoV-2 and COVID-19 Research
- Cancer Genomics and Diagnostics
- Medical Imaging and Pathology Studies
- RNA modifications and cancer
- Systemic Lupus Erythematosus Research
- Cholangiocarcinoma and Gallbladder Cancer Studies
Chang Gung University
2016-2025
Chang Gung Memorial Hospital
2016-2025
John Wiley & Sons (United Kingdom)
2021-2023
Hepatitis B Foundation
2023
Yonsei University
2023
Linkou Chang Gung Memorial Hospital
2018-2022
Hanover College
2019-2021
Hudson Institute
2021
National Taiwan University Hospital
2005-2016
Kaohsiung Chang Gung Memorial Hospital
1989-2016
The effectiveness of antiviral therapy in preventing disease progression patients with chronic hepatitis B and advanced fibrosis or cirrhosis is unknown.
The presence of hepatitis B e antigen (HBeAg) in serum indicates active viral replication hepatocytes. HBeAg is thus a surrogate marker for the virus DNA. We conducted prospective study to determine relation between positivity surface (HBsAg) and development hepatocellular carcinoma.
Abstract One year of treatment with entecavir (0.5 mg daily) in nucleoside-naive patients hepatitis B e antigen (HBeAg)-positive or HBeAg-negative chronic (CHB) resulted significantly improved liver histology and virological biochemical endpoints comparison lamivudine. Patients who received at least 3 years cumulative therapy phase studies a long-term rollover study underwent biopsy were evaluated for improvements histological appearance. Sixty-nine [50 HBeAg-positive 19 HBeAg-negative]...
Large amounts of new data on the natural history and treatment chronic hepatitis B virus (HBV) infection have become available since 2005. These include long-term follow-up studies in large community-based cohorts or asymptomatic subjects with HBV infection, further role genotype/naturally occurring mutations, drug resistance therapies. In addition, Pegylated interferon alpha2a, entecavir telbivudine been approved globally. To update management guidelines, relevant were reviewed assessed by...
Reducing hepatitis B virus (HBV) replication to minimal levels is emerging as a key therapeutic goal for chronic B.
During the course of chronic hepatitis B virus (HBV) infection, e antigen (HBeAg) seroconversion to its antibody (anti-HBe) often coincides with normalization liver biochemical test and clinical remission, but data regarding long-term outcome after spontaneous are still scarce. Excluding patients other virus(es) concurrent 283 HBV infection were followed up for at least 1 year HBeAg anti-HBe. Follow-up studies included clinical, biochemical, virologic evaluation hepatocellular carcinoma...
BackgroundThe risk of hepatocellular carcinoma (HCC) increases with increasing level hepatitis B virus (HBV) in serum (viral load). However, it is unclear whether genetic characteristics HBV, including HBV genotype and specific mutations, contribute to the HCC. We examined HCC associated genotypes common variants precore basal core promoter (BCP) regions.
Although chronic infection with hepatitis B virus (HBV) has been established as a cause of hepatocellular carcinoma (HCC), the roles viral load and HBV genotype remain unclear.From 1988 through 1992, baseline blood samples were collected from 4841 Taiwanese men who carriers but had not diagnosed HCC. We used real-time polymerase chain reaction assays plasma DNA to quantify levels (a measure load) determine genotypes for 154 case patients HCC during 14 years follow-up 316 control subjects....
Lamivudine is a potent inhibitor of hepatitis B virus (HBV) replication, but its long-term use may be associated with HBV tyrosine-methionine-aspartate-aspartate (YMDD) motif mutation. To examine the clinical features and course after emergence YMDD mutants, 55 patients who received lamivudine therapy over 104 weeks at our unit were assayed for mutation(s). Thirty-two them found to have They continued followed up weekly or biweekly if clinically indicated. Thirty (93.7%) showed elevation...
Hepatitis B virus DNA (HBV DNA) in serum was measured by a Spot hybridization technique consecutive series of 79 cases with chronic HBV infection from Taiwan. found 96.3% (52/54) HBeAg-positive, 66% (2/3) neither HBeAg or anti-HBe and 63.6% (14/22) positive patients. The levels the HBe-Ag-positive patients were significantly higher than (median, 944 vs. 58 pg per ml, p less 0.001). mean ages increased 28.7 years for high DNA, to 34.7 those low (p 0.01) 41.0 without 0.05 when compared level...
Data are limited on the safety and effectiveness of oral antivirals other than lamivudine adefovir dipivoxil for treatment chronic hepatitis B (CHB) in patients with decompensated liver disease. This Phase 2, double-blind study randomized 112 CHB disease to receive either tenofovir disoproxil fumarate (TDF; n = 45), emtricitabine (FTC)/TDF (fixed-dose combination; or entecavir (ETV; 22). The primary endpoint was safety; more specifically, tolerability failure (adverse events resulting...
Hepatitis B surface antigen (HBsAg) loss is a rare event during nucleos(t)ide analogue (Nuc) therapy. Limited data suggest that stopping Nuc therapy may increase HBsAg rate in hepatitis e antigen–negative patients. A large study was conducted to investigate this issue more detail. Of the 1,075 patients treated with for median of 156 (61‐430) weeks, 5 showed seroclearance treatment at an estimated annual incidence 0.15%. who remained HBsAg‐seropositive, 691 (52.3 years old, 86% male, 44.6%...
Purpose Counseling patients with chronic hepatitis B virus (HBV) on their individual risk of liver disease progression is challenging. This study aimed to develop nomograms for predicting hepatocellular carcinoma in B. Patients and Methods Two thirds the Risk Evaluation Viral Load Elevation Associated Liver Disease/Cancer–Hepatitis Virus (REVEAL-HBV) cohort was allocated model derivation (n = 2,435), remaining third validation 1,218). Previously confirmed independent predictors included...
On-treatment levels of hepatitis B surface antigen (HBsAg) may predict response to peginterferon (PEG-IFN) therapy in chronic (CHB), but previously proposed prediction rules have shown limited external validity. We analyzed 803 HBeAg-positive patients treated with PEG-IFN three global studies available HBsAg measurements. A stopping-rule based on absence a decline from baseline was compared prediction-rule that uses <1,500 IU/mL and >20,000 identify high low probabilities response....
The optimal duration of nucelos(t)ide analog (Nuc) treatment in hepatitis B e antigen (HBeAg)-negative patients with chronic virus (HBV) infection is unknown. Asian Pacific Association for the Study Liver (APASL) guidelines recommend that can be discontinued if undetectable HBV-DNA has been documented on three occasions ≥6 months apart. This study aimed to test this stopping rule HBeAg-negative (CHB) treated entecavir (ETV). Ninety-five (39 cirrhosis) were ETV a median 721 (395-1,762) days...